NY-SOLIDUS-LABS
Solidus Labs , the category-definer for crypto-native market integrity solutions, announced today the launch of HALO , the first automated, comprehensive and testable trade surveillance and market integrity hub tailored for digital assets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005138/en/
HALO’s launch will be instrumental in shaping the future of financial risk monitoring. Built from the ground up to bridge the gap between crypto and traditional finance, HALO provides Wall-Street grade crypto-native regulatory risk and compliance solutions. Increasingly, financial institutions are relying on HALO as they expand into new revenue opportunities offered by digital assets. Beyond a growing client-base of crypto and DeFi businesses, HALO is also set to offer government agencies tools to create transparency, enable innovative regulatory frameworks and ensure safe and regulated crypto financial services in their jurisdictions. The platform addresses numerous crypto-specific challenges, like new market structures, volatility, volumes, data types, decentralized services, trading dynamics, crypto-native market abuse typologies - and evolving business and regulatory demands.
“Crypto’s potential to make financial services more accessible, transparent, liquid and efficient, depends on state-of-the-art financial risk monitoring that enables the merits of digital assets, while surgically mitigating its many new risks,” said Asaf Meir, Founder and CEO of Solidus Labs. “HALO does that by unifying formerly disparate risk data points, and continually monitoring that data in real-time, creating a behavioral-based universal client risk profile that allows our clients to focus on real risk, in real-time, throughout the investment journey.”
Combining cutting edge machine learning technology and decades of traditional financial risk know-how and best practices, HALO is uniquely tailored to address the “triple T” (T3) pillars of market integrity in the crypto and DeFi space - trade surveillance, transaction monitoring, and threat intelligence. HALO’s modules include:
Trade Surveillance: HALO’s comprehensive market surveillance tools ensure market integrity by benchmarking abnormal crypto orders and execution patterns against the market norm, to alert businesses and networks on potential breaches of trading rules or unusual market volatility. HALO users can easily customize detection model sensitivity and backtest against real data in order to meet the needs of quickly evolving regulatory and compliance landscapes.
Transaction monitoring: HALO’s continuous real-time monitoring of crypto and fiat transactions offers unprecedented blockchain-native capabilities and enables detecting, investigating and reporting suspicious crypto deposits and withdrawals for anti-money laundering (AML), sanctions, and financial risk compliance.
Threat Intelligence: Relying on a built-in onboarding verification tool, powerful integrations and crypto-native infrastructure, HALO’s Universal Client Risk Profile aggregates risk across the entire investment journey and multiple markets - from onboarding to trading, post-trade and everything in between. Synthesizing numerous signals into a single threat intelligence hub, HALO surgically surfaces overlooked threats in crypto and DeFi services, enabling businesses to act upon them in real time.
HALO currently protects more than 25 million retail and institutional investors globally, and is actively used to monitor over one trillion events per day. The platform deploys over 50 different proprietary market abuse typologies, shielding investors and safeguarding crypto businesses from new threats unique to the crypto and decentralized finance space. “Since our founding, our deepest commitment has been to enable a safer crypto ecosystem. HALO brings us one step closer to that goal while taking user experience to the next level, empowering risk and compliance teams and allowing crypto businesses to grow safer,” Meir said. “It’s a culmination of thousands of hours of work with crypto teams and discussions with regulators, fulfilling our vision of harnessing crypto not only as an opportunity to transform financial services, but also as an opportunity to take financial risk monitoring into the future.”
To learn more about Solidus Labs and HALO visit: www.soliduslabs.com
About Solidus Labs:
Solidus Labs is the category-definer for crypto-native triple T (T3) market integrity solutions - trade surveillance, transaction monitoring, and threat intelligence.
Our mission is to enable safer crypto trading throughout the investment journey across all centralized and DeFi markets. As the founder of industry leading initiatives like the Crypto Market Integrity Coalition and DACOM Summit , and in everything we do, Solidus is deeply committed to ushering in the financial markets of tomorrow.
Crypto exchanges, financial institutions and regulators globally rely on Solidus HALO - our real time, comprehensive, testable, and future-proof platform. Safeguarding their business from known forms of market abuse and a plethora of emerging crypto-specific risks, we enable our clients to grow faster - and safer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005138/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom